Health
Minghui Pharmaceutical Announces Promising Initial Results from Phase I Clinical Trial of MHB039A, a Novel PD-1 x VEGF Bispecific Antibody, in Patients with Relapsed/Refractory Solid Tumors
SHANGHAI, Nov. 6, 2024 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a late-stage biopharmaceutical company focused on developing transformative medicines in immunology and oncology, today announced initial results from its Phase I clinical trial of MHB039A, a novel PD-1 x VEGF bispecific antibod...
2024-11-06 18:00
2940
CROWN AESTHETICS PROVIDES CAVENDISH CLINICS WITH AWARD-WINNING SKINPEN® PRECISION TO UPGRADE ITS MICRONEEDLING DEVICE OFFERING
LONDON, Nov. 6, 2024 /PRNewswire/ -- Crown Aesthetics, a Crown Laboratories company and leading innovator in the dermatologic and aesthetics industry, is proud to announce that Cavendish Clinics, one of theUnited Kingdom's ("UK") premier aesthetic clinic groups, has upgraded their microneedling d...
2024-11-06 17:00
1233
ASH 2024 | Results From Three Clinical Studies of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax Selected for Presentations, Including an Oral Report
ROCKVILLE, Md. and SUZHOU, China, Nov. 6, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that the latest results...
2024-11-06 16:09
1401
ASH 2024 | Studies of Olverembatinib Selected for Presentations, Including an Oral Report, for the Seventh Consecutive Year
ROCKVILLE, Md. and SUZHOU, China, Nov. 6, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that multiple studies o...
2024-11-06 15:56
1589
Hanmi Unveils Novel Obesity Drug 'HM17321' : A Game-Changer in Overcoming GLP-1-Associated Muscle Loss
Fat Loss Augmentation + Lean Mass Increase Hanmi Presents Three Breakthrough Findings on Novel Obesity Drugs at 2024 ObesityWeek High Quality Obesity Management by Targeting the CRF2 Receptor: Enhanced Fat Loss with Lean Mass Increase Improved Weight Loss and Muscle Preservation with HM15275 Comb...
2024-11-06 15:41
1046
Leads Biolabs Receives Orphan Drug Designation from the US FDA for LBL-034, a Uniquely Designed, Highly Differentiated Anti-GPRC5D/CD3 Bispecific Antibody, for the Treatment of Multiple Myeloma
NANJING, China, Nov. 6, 2024 /PRNewswire/ -- On November 1, Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs") announced that LBL-034, a humanized bispecific T-cell engaging antibody targeting both GPRC5D and CD3 which is independently developed by Leads Biolabs with glo...
2024-11-06 15:20
1200
QureBio Ltd. to Present its Q-1802 Clinical PhaseⅡ Data at 2024 SITC 39th Annual Meeting
SHANGHAI, Nov. 6, 2024 /PRNewswire/ -- QureBio Ltd., a clinical-stage biopharmaceutical company focusing on development of bispecific antibodies and other engineered Biopharmaceuticals for the treatment of cancer, inflammation, and other serious disorders, today announced that Phase Ⅱ Clinical Da...
2024-11-06 13:00
1124
Duoning Biotech announced strategic partnership with Branca Bunús to promote the next generation of transfection reagents
SHANGHAI, Nov. 5, 2024 /PRNewswire/ -- Duoning Biotechnology Group ("Duoning") announced a strategic partnership agreement with Branca Bunús Ltd. ("Branca Bunús"). Under this agreement, the two companies will collaborate on the development, optimization, and application of transfection reagents, ...
2024-11-06 09:24
1156
Antengene Presents Results from Three Investigational Programs at the 2024 SITC Annual Meeting
SHANGHAI and HONG KONG, Nov. 6, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cance...
2024-11-06 09:08
1391
Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024
SHANGHAI and HONG KONG, Nov. 6, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cance...
2024-11-06 08:30
1427
MedAdvisor Solutions Launches Telehealth Service on MedAdvisor Patient App, Further Enhancing Access to Care
Patients can now book virtual provider consultations within the App MELBOURNE, Australia, Nov. 6, 2024 /PRNewswire/ -- MedAdvisor Solutions, a global leader in pharmacy-driven patient engagement solutions, announced today that new Telehealth functionality is now available within the MedAdvisor ...
2024-11-06 06:47
1395
Inside Infinitus: Innovating Customer Service Excellence in China
GUANGZHOU, China, Nov. 6, 2024 /PRNewswire/ -- "Hello, thank you for calling!" This familiar phrase is often heard when dialing into customer service hotlines. The "heard yet unseen" centers, staffed by professionals adept at listening and addressing customer concerns, form the backbone of the se...
2024-11-06 03:04
1360
Medeologix Expands Hydrophilic Coating Services, Partners with Biocoat® Incorporated to Solidify Position as The Bay Area's Premier Catheter Solutions Provider
SAN JOSE, Calif., Nov. 5, 2024 /PRNewswire/ -- Medeologix, a leading brand in medical device manufacturing, today announced a significant expansion of its end-to-end catheter solutions with the addition of hydrophilic coating services, further cementing its status as the Bay Area's premier choice...
2024-11-06 00:00
1002
Complete Genomics Announces Spatial Omics Distributor Agreement, Debuts Spatial Xcellerator Grant Program at SITC 2024
HOUSTON, Nov. 5, 2024 /PRNewswire/ -- At the Society for Immunotherapy of Cancer (SITC) Annual Meeting (Nov. 6-10, 2024), Complete Genomics, a pioneering genomic sequencing company, is pleased to announce the launch of its Spatial Xcellerator grant program as the exclusive distributor of STOmics'...
2024-11-05 22:00
1111
Dong'e Ejiao Continues to Propel Traditional Chinese Medicine onto the Global Stage
Harnessing Tradition and Innovation: Dong'e Ejiao's Seventh Appearance at the CIIE SHANGHAI, Nov. 5, 2024 /PRNewswire/ -- On November 5th, the 7th China International Import Expo (CIIE) opened inShanghai. A key player in China Resources Group's healthcare sector, Dong'e Ejiao Co., Ltd. (hereinaf...
2024-11-05 18:09
1262
J INTS BIO Launches AI-Supercomputing Alliance to Transform Cancer Therapy
- Yuhan Corporation CEO Wook Je Cho, National Assembly Member Seong Hoon Park, and KAIST ProfessorJoung Ho Kim join a pioneering collaboration in precision oncology. SEOUL, South Korea, Nov. 5, 2024 /PRNewswire/ -- On November 4, 2024, J INTS BIO hosted a significant MOU signing ceremony at Baek...
2024-11-05 17:38
958
4th World Health Forum explores role of AI in global health
BEIJING, Nov. 5, 2024 /PRNewswire/ -- This is a report from China.org.cn: The Fourth World Health Forum, hosted by Tsinghua University, opened in Beijing on Saturday with the theme, "AI Empowers the Future of Health." The two-day event has brought together over 200 experts, government officials, ...
2024-11-05 16:52
935
FWD Group announces strong new business growth update
HONG KONG, Nov. 5, 2024 /PRNewswire/ -- FWD Group Holdings Limited ("FWD Group" or "FWD") today announced strong new business growth highlights for the nine months ended30 September 2024. * Value of new business (VNB) of US$623 million, with underlying[i] year-on-year growth of 16 per cent, ...
2024-11-05 16:30
1310
The Adecco Group: Q3 2024 RESULTS
Robust performance in challenging markets; volumes stabilising ZURICH, Nov. 5, 2024 /PRNewswire/ -- * Revenues -5% yoy organic TDA, -3% yoy organic, a solid result given market conditions, high comparison base; volumes stabilising * By GBU, Adecco -5%, with good results across Asia, Iberia, E...
2024-11-05 13:45
1173
BioCity presents late-breaking clinical trial results with SC0062 for IgA Nephropathy at ASN Kidney Week 2024 as published in the Journal of the American Society of Nephrology
SHANGHAI, Nov. 4, 2024 /PRNewswire/ -- BioCity Biopharma (BioCity) announced late-breaking results of the 2-SUCCEED clinical trial of SC0062, a selective endothelin receptor type A (ETA) antagonist, for the treatment of IgA Nephropathy (IgAN). These results were presented at the Oral Abstract Ses...
2024-11-05 11:09
1413
Week's Top Stories
Most Reposted
Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 305 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 299 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
[Picked up by 296 media titles]
2024-11-15 15:25
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 283 media titles]
2024-11-20 09:00
Most Read
Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
2024-11-15 15:25
8674
How "small apples" march into "big industry" in Yan'an
2024-11-15 17:39
5354
Yingli Solar's Global Product Workshops Launched in Malaysia
2024-11-15 21:40
4730
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
4681